Although, cognitive outcomes have not been assessed in clinical trials of selumetinib, a cognitive study conducted across multiple ongoing MEK inhibitor trials in NF1 patient populations found potential benefits to some measures of memory (Walsh et al., 2021), indicating that MEK inhibitors might prove more effective than statins. This evidence concerns the gene MAP2K7 and neurofibromatosis type 1.